Angel and TransGenRx Inc. sign contract (4340B)
April 17 2012 - 2:00AM
UK Regulatory
TIDMABH
RNS Number : 4340B
Angel Biotechnology Holdings Plc
17 April 2012
17(th) April 2012
Angel Biotechnology Holdings plc
("Angel" or "the Company")
Angel Biotechnology Holdings and TransGenRx Inc. sign contract
for
development of a recombinant interferon product.
Angel Biotechnology Holdings plc, (AIM:ABH), the
biopharmaceutical contract manufacturer, is pleased to announce
that it has agreed a contract with TransGenRx Inc. (Baton Rouge,
USA) for the development and scale up of a recombinant interferon
product. The purpose of the contract is to attain acceptable
expression levels on which to establish a GMP manufacturing
process, which would then be conducted by Angel. This development
work for TransGenRx will take place at Angel's GMP facility at
Cramlington and will have a value in excess of GBP800,000.
Dr Stewart White, Acting CEO and Commercial Director, Angel
Biotechnology Holdings, said:
"This contract demonstrates the confidence which TransGenRx has
in the ability of Angel to develop and manufacture complex proteins
and reinforces the board's decision to invest in this additional
capacity. We look forward to taking this product through to GMP
manufacturing in our Cramlington facility and to a long and
fruitful relationship between our respective companies."
Dr Richard Cooper, CSO, "TransGenRx Inc.", said:
"The development and production of this interferon product is
key to the future of TransGenRx, hence the reason we have entrusted
its delivery to the team at Angel. We are confident this will be
the first of a number of projects that we would like to progress
with Angel".
For further information:
Angel Biotechnology Holdings plc
Lorna Peers, Finance Director +44 (0) 131 445 6077
Stewart White, Acting CEO/Commercial Director
www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383
5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029
ariane.comstive@communications-portfolio.co.uk
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract
bio-manufacturing partner to biotechnology and pharmaceutical
companies worldwide. Angel specialises in advanced biologics
including biopharmaceutical proteins and cell therapies, such as
cellular vaccines and stem cells. At present, Angel's products are
principally used in pre-clinical studies and clinical trials with a
view to becoming the contract manufacturer of choice on a
continuing basis.
Drug development companies outsource their biopharmaceutical
manufacturing requirements to Angel to reduce their own capital
requirements and enable them to develop products more rapidly. In
addition, Angel provides complete regulatory services and
documentation to its customers while its manufacturing processes
adhere to the most stringent regulatory requirements. Products are
produced to current Good Manufacturing Practice (cGMP) standards as
required by the US Food and Drug Administration (FDA), and in
facilities that are certified to European standards by the
Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from early-stage biotechnology companies
including ReNeuron plc and US-based Pathfinder Cell Therapy, to
established pharmaceutical companies such as Russian-based Materia
Medica Holdings.
Angel has two facilities: Pentlands Science Park near Edinburgh
where it employs 38 people, and a site in Cramlington, near
Newcastle-upon-Tyne, which is expected to employ up to 10 people by
the end of 2012.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTGGUGWCUPPGAQ
Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From Apr 2024 to May 2024
Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From May 2023 to May 2024